Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 2/20 | 0.39 |
| ▸ | NOS1 | P29475 | 2/20 | 0.39 |
| ▸ | NOS2 | P35228 | 2/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | PAX8 | Q06710 | 3/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 2/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL317914 | 1.00 | NOS3 (0.39) | NOS3NOS1NOS2CYP19A1CYP11B1 | |
| SCHEMBL10109367 | 1.00 | NOS3 (0.39) | NOS3NOS1NOS2CYP19A1CYP11B1 | |
| SCHEMBL10109398 | 0.89 | NOS3 (0.40) | NOS3NOS1NOS2CYP19A1CYP11B1 | |
| SCHEMBL317938 | 0.89 | NOS3 (0.40) | NOS3NOS1NOS2CYP19A1CYP11B1 | |
| SCHEMBL10109408 | 0.88 | NOS3 (0.39) | NOS3NOS1NOS2CYP19A1CYP11B1 | |
| SCHEMBL317677 | 0.88 | NOS3 (0.39) | NOS3NOS1NOS2CYP19A1CYP11B1 | |
| SCHEMBL318288 | 0.85 | CYP19A1 (0.38) | NOS3NOS1NOS2CYP19A1CYP11B1 | |
| SCHEMBL10109394 | 0.85 | CYP19A1 (0.38) | NOS3NOS1NOS2CYP19A1CYP11B1 | |
| SCHEMBL318329 | 0.84 | CHRNA7 (0.39) | — | |
| SCHEMBL10109395 | 0.84 | CHRNA7 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093302-B2 | Substituted tetralins as selective estrogen receptor-β agonists | ELI LILLY AND COMPANY (US) | 2012-01-10 | — | — | US | disclosed |
| US-20100249075-A1 | SUBSTITUTED TETRALINS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS | ELI LILLY AND COMPANY (US) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249075-A1 | SUBSTITUTED TETRALINS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS | ESR2, ERLIN1, ESRRG | NOS3 3463/4885NOS1 3050/4885NOS2 2891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.